Document:

Employment Agreement between Registrant and Fernand Labrie

 Exhibit 10.1 
 THIS EMPLOYMENT AGREEMENT entered into at Quebec City (Quebec) on the date hereinafter mentioned, 
  

			
	BETWEEN:	  	ENDOCEUTICS, INC., a corporation duly constituted, having its principal place of business at 2989, de la Promenade, Québec, Québec, G1W 2J5, herein acting and
represented by Mr. Robert Després, its Chairman;
		
		  	(hereafter “EndoCeutics”)
		
	AND:	  	DR. FERNAND LABRIE, domiciled and resident at 2989, de la Promenade, Québec, Québec, G1W 2J5;
		
		  	(hereafter “Dr. Labrie”)

 WHEREAS EndoCeutics desires to secure an agreement from Dr. Labrie that Dr. Labrie will provide
his ongoing business time, energy and skills to EndoCeutics as an employee holding the position of President, Chief Executive Officer and Chief Scientific Officer of EndoCeutics; 
 WHEREAS Dr. Labrie desires to provide EndoCeutics with such agreement and obtain certain assurances from EndoCeutics; 
 NOW THEREFORE, in consideration of the mutual promises and covenants set forth herein, the parties hereto agree as follows: 
  

	1.	EFFECTIVE DATE AND TERM OF EMPLOYMENT 

  

	1.1	This Employment Agreement shall begin on the Effective Date, (as defined in Article 18) and shall continue until it is terminated pursuant to section 9 herein.

  

	2.	DUTIES 

  

	2.1	As President, Chief Executive Officer and Chief Scientific Officer of EndoCeutics, Dr. Labrie shall perform all services, acts and other things necessary or advisable to
manage and conduct the business of EndoCeutics. Dr. Labrie shall also assume, in addition to the functions and duties inherent and related to his position, the functions and duties that the Board of Directors of EndoCeutics may from time to
time delegate to him. Dr. Labrie shall report directly to the Board of Directors of EndoCeutics. 

  

	3.	BASIC SALARY, BENEFITS AND EXPENSES 

  

	3.1	EndoCeutics will pay to Dr. Labrie a base salary of CDN$260,000.00 per year, payable by 24 equal and consecutive installments of CDN$10,833.34 (or in such equal and
consecutive installments as are consistent with EndoCeutics’ current payroll practices), less payroll deductions and all required withholdings. Dr. Labrie’s remuneration may be adjusted in accordance with EndoCeutics’ policies
and procedures. 

	3.2	Dr. Labrie will also be eligible to participate in such of EndoCeutics’ benefit plans as are now generally available or later available to executives of
EndoCeutics, subject to the terms of those plans. 

  

	3.3	Pursuant to EndoCeutics’ customary policies in force at the time of payment, Dr. Labrie shall be promptly reimbursed, against presentation of vouchers or receipts
therefore, for all expenses properly incurred on behalf of or to further the business interest of EndoCeutics in the performance of his duties hereunder. 

  

	4.	BONUS 

  

	4.1	EndoCeutics further agrees to pay to Dr. Labrie, as an additional consideration, an annual bonus based on the performance of Dr. Labrie and on the achievement of
the objectives to be fixed by the Board of directors of EndoCeutics from year to year. 

  

	4.2	Said bonus may reach 50% of his base salary if targeted results and objectives are achieved. It may double for exceptional results and performance. Said bonus shall be
reviewed by the Compensation Committee from year to year and shall be paid from the financial year-end of EndoCeutics. From the bonus amount, EndoCeutics will deduct all normal employment deductions including contributions to various governments.

  

	5.	VACATION 

  

	5.1	Dr. Labrie is entitled to 4 weeks of paid vacation annually from the Effective Date onwards. Such vacations shall be consistent with EndoCeutics’ vacation policies.

  

	6.	STOCK OPTIONS 

  

	6.1	As President and Chief Executive Officer of EndoCeutics, and following the commencement of Dr. Labrie’s employment with EndoCeutics, Dr. Labrie will be
eligible to a stock option under the EndoCeutics’ Stock Option Plan to purchase EndoCeutics’ Common Shares (the “Option”). The Option will be governed by and granted pursuant to a separate stock option agreement and the
Plan. In addition, Dr. Labrie shall be entitled to participate in any stock option plan, stock appreciation rights, incentive stock plan or restricted stock plan or other similar plan that may be implemented from time to time by EndoCeutics and
as recommended by the Compensation Committee. 

  

	7.	LOYAL AND CONSCIENTIOUS PERFORMANCE 

  

	7.1	During the term of this Employment Agreement, Dr. Labrie shall, subject to section 7.2, devote all of his business time, energy and skills to the affairs of EndoCeutics
and use his best efforts to promote the interests of EndoCeutics; provided that, Dr. Labrie shall not be precluded from (i) engaging in civic, charitable or religious activities which do not 

 present any conflict of interest with EndoCeutics or affect Dr. Labrie’s performance of duties
and functions for EndoCeutics or (ii) assisting or being a member of the Board of Directors of any company which is not a direct competitor of EndoCeutics subject to obtaining prior written consent from EndoCeutics. 
  

	7.2	EndoCeutics recognizes that as of the Effective Date, Dr. Labrie is a member of the following Boards of Directors and/or an officer and/or an employee of the following
organizations and hereby authorizes Dr. Labrie to continue to sit on these Boards of Directors and/or to act such capacity: Pôle Québec-Chaudières Appalaches, Fondation du CHUQ, Fondation du cancer de la prostate, Advitech
inc., EndoResearch inc., MedcoPharma inc., 2751-8901 Québec inc., 9165-7825 Québec inc., CHUL Research Centre, Corporation des chercheurs et chercheures du Centre de recherche du CHUL and Laval University. 

  

	7.3	This Agreement shall not be interpreted to prohibit Dr. Labrie from making passive personal investments or conducting private business affairs if such activities do not
materially interfere with the services required under this Agreement. 

  

	8.	NON-COMPETITION AND NON-SOLICITATION 

  

	8.1	Dr. Labrie shall not, during the term of this Employment Agreement and for a period of twelve (12) months immediately following the termination of his employment, become
engaged, directly or indirectly as an employee, consultant, partner, principal, agent, proprietor, shareholder (other than a holding of shares listed on a stock exchange that does not exceed 2% of the outstanding shares so listed) or advisor, in a
business in the territory of the United States and Canada that (i) conducts research, development, marketing, sales or manufacturing activities in the field of breast and prostate cancer using antiandrogens, antiestrogens or SERMs and
women’s health and aging using DHEA, SERMs or SARMs and (ii) is a direct competitor of EndoCeutics. Dr. Labrie acknowledges that the restrictions contained in this section 8.1 are properly required for the adequate protection of
EndoCeutics’ businesses and that said restrictions do not materially affect his ability to obtain other employment. 

  

	8.2	Dr. Labrie shall not, during the term of this Employment Agreement and for a period of twelve (12) months immediately following the termination of his employment,
directly or indirectly solicit any employees of EndoCeutics and shall not solicit or induce or attempt to induce any person who were employees of or consultants to EndoCeutics at the time of such termination (or during the ninety (90) days
immediately preceding such termination), to terminate their employment or consulting agreement with EndoCeutics. 

  

	8.3	These Non-Competition (8.1) and Non-Solicitation (8.2) provisions shall not be applicable if EndoCeutics effects a Termination without Cause of
Dr. Labrie’s employment (as defined in section 9.3), or if Dr. Labrie’s employment is terminated following a merger or acquisition (as defined in section 9.4). 

	8.4	Employee acknowledges and agrees that the agreements and covenants set forth in the Non-Competition (8.1) and Non-Solicitation (8.2) are reasonable and necessary
for the protection of the Company’s business interests, that irreparable injury will result to the Company if employee breaches any of the terms of said covenants, and that in the event of employee’s actual or threatened breach of any such
covenants, the Company will have no adequate remedy at law. Employee accordingly agrees that, in the event of any actual or threatened breach by employee of any of said covenants, the Company will be entitled to immediate injunctive and other
equitable relief, without bond and without the necessity of showing actual monetary damages. Nothing in this paragraph 8.4 will be construed as prohibiting the Company from pursuing any other remedies available to it for such breach or threatened
breach, including the recovery of any damages that it is able to prove. Each of the covenants in sections 8.1 and 8.2 will be construed as independent of any other covenants or other provisions of this Agreement. 

  

	9.	TERMINATION 

  

	9.1	Disability. If during the terms of this Agreement, Dr. Labrie becomes ill, disabled or otherwise incapacitated so as to be unable to perform his usual duties
(a) for a period in excess of one hundred and eighty (180) consecutive days and this incapacity has not been remedied within one (1) year of the first day of disability, or (b) for more than two hundred and seventy
(270) days in any consecutive eighteen (18) month period and this incapacity has not been remedied within eighteen (18) months of the first day of disability, then EndoCeutics shall have the right to terminate this Agreement, subject
only to applicable laws, on thirty (30) day’s notice to Dr. Labrie. Termination pursuant to this section 9.1 shall not affect any rights Dr. Labrie may otherwise have under any disability insurance policies in effect at the time
of such termination. 

  

	9.2	Discharge for cause. EndoCeutics may discharge Dr. Labrie and terminate his employment under this Agreement for cause without further liability to EndoCeutics by
the positive vote of 2/3 of the members of the Board of Directors of EndoCeutics except that Dr. Labrie, if a Director, shall not be entitled to vote thereon. As used in this section 9.2, “cause” shall mean any or all of the
following: 

	 	(a)	gross or willful misconduct of Dr. Labrie during the course of his employment; 

  

	 	(b)	conviction of any criminal offence involving dishonesty, breach of trust or moral turpitude during the term of this Agreement; or 

  

	 	(c)	Dr. Labrie’s breach of any of the material terms of this Agreement. 

  

	9.3	Termination without cause. Upon thirty (30) days prior written notice, EndoCeutics may terminate this Agreement without cause by a positive vote of 2/3 of the
members of the Board of Directors of EndoCeutics except that Dr. Labrie, if a Director, shall not be entitled to vote thereon. EndoCeutics shall incur no liability in this regard except that it shall continue to pay Dr. Labrie the
remuneration he is entitled to at his then current rate for a twenty-four (24) month period after termination if termination shall occur prior to the 

 events mentioned in section 9.4. In addition, any outstanding stock options that have not vested in
accordance with their terms will become fully vested and shall be exercised by Dr. Labrie within a period of twenty-four (24) months from the time of such termination or shall be automatically terminated immediately following such
twenty-four (24) month period. 
  

	9.4	Termination following merger or acquisition. If EndoCeutics merges or consolidates with another corporation, if substantially all of the assets of EndoCeutics are sold,
if a majority of the outstanding stock of EndoCeutics is acquired by another person, or if a majority of the independent members of the Board of Directors are replaced at the same time or over a period of twelve (12) months and
Dr. Labrie’s employment is subsequently terminated by EndoCeutics or surviving entity other than for cause as described in 9.2, Dr. Labrie shall be entitled to 24 months’ remuneration plus health benefits.

 In addition to the foregoing, any outstanding stock options (including substituted stock options of the acquiring or
surviving corporation in such merger or acquisition) which have not vested in accordance with their terms will become fully vested and shall be exercised by Dr. Labrie within a period of twenty-four (24) months from the time of such
termination or shall be automatically terminated immediately following such twenty-four (24) month period. For purposes of this section 9.4, Dr. Labrie shall be entitled to treat a material demotion in title or function or a physical
relocation of worksite of more than 50 km as termination under this section 9.4, but only if Dr. Labrie expressly so notifies EndoCeutics and terminates his employment hereunder within thirty (30) days of such demotion or relocation.
If Dr. Labrie is offered a substantially similar position with the surviving entity and a physical relocation (beyond a 50 km radius from Dr. Labrie’s regular worksite) is required by such position, Dr. Labrie’s refusal
to accept such position shall not be treated as subject to termination by Dr. Labrie under section 9.5. 
  

	9.5	Voluntary termination by Dr. Labrie. In the event of voluntary termination by Dr. Labrie, Dr. Labrie shall be entitled only to those amounts that have
accrued to the date of termination in accordance with the terms hereof or are expressly payable under the terms of EndoCeutics applicable benefit plans or are required by applicable law. In addition, and notwithstanding the terms and conditions of
any stock option plan governing the options held by Dr. Labrie, any outstanding stock options that have vested in accordance with their terms shall be exercised by Dr. Labrie within a six (6) month period. Any outstanding stock
options that have not vested in accordance with their terms and conditions shall become null and void. EndoCeutics may, in its sole and absolute discretion, confer such other benefits or payments as it determines, but Dr. Labrie shall have no
entitlement thereto. 

  

	10.	CONFIDENTIALITY, PROPRIETARY INFORMATION AND INVENTION AGREEMENT 

  

	10.1	Dr. Labrie will execute and deliver to EndoCeutics a Confidentiality, Proprietary Information and Invention Agreement in the form attached hereto as Schedule A on or
before the Effective Date. 

	11.	WAIVER 

  

	11.1	The waiver of any term or condition of this Agreement by any party shall not be construed as a waiver of a subsequent breach or failure of the same term or condition, or a
waiver of any other term or condition of this Agreement. 

  

	12.	NOTICES 

  

	12.1	All notices, requests, demands, and other communications made in connection with this Employment Agreement shall be in writing and shall be deemed to have been duly given on
the date of delivery if delivered by hand delivery or five (5) days after mailing if mailed by certified or registered mail postage with prepaid return receipt requested. Addresses are as follows: 

  

			
	If to ENDOCEUTICS:	  	2989, de la Promenade
		  	Québec, Québec
		  	G1W 2J5
		  	Attn: Chairman
		
	If to Dr. Labrie:	  	2989, de la Promenade
		  	Québec, Québec
		  	G1W 2J5

 Any party may change its address for notices by notices duly given pursuant to this section.

  

	13.	SEVERABILITY 

  

	13.1	In case any or some of the provisions of this Agreement shall be held to be invalid, illegal or unenforceable for any reason, such invalidity, illegality or unenforceability
shall not affect the other provisions of this Agreement, and this Agreement shall be construed as if such invalid, illegal or unenforceable provision had never been contained herein. 

  

	14.	ENTIRE AGREEMENT AND MOFIDICATIONS 

  

	14.1	Except as otherwise provided herein, this Employment Agreement, together with its Schedule A, represents the entire understanding between the parties with respect to the
subject matter hereof, and this Employment Agreement supersedes any and all prior understandings, agreements, plans and negotiations, written or oral, with respect to the subject matter hereof. All modifications to the Employment Agreement must be
in writing and signed by the parties against whom enforcement of such modification is sought, provided that no modification shall be enforceable against EndoCeutics unless signed by a duly authorized member of its Board or Directors.

	15.	GOVERNING LAW AND JURISDICTION 

  

	15.1	This Employment Agreement shall be governed by and construed in accordance with the laws of the Province of Quebec and the courts of the judicial district of Quebec shall
have jurisdiction. 

  

	16.	SUCCESSORS AND ASSIGNS 

  

	16.1	This Employment Agreement shall be binding upon and inure to the benefit of the executors, administrators, heirs, successors and assigns of the parties; provided, however,
that this Employment Agreement shall not be assignable by EndoCeutics or by Dr. Labrie. 

  

	17.	CONFIDENTIALITY 

  

	17.1	The parties hereby agree to keep the terms hereof confidential, subject to (i) any disclosure hereof required by law or regulation, and (ii) the ability of a party
to review the terms hereof with its legal, accounting and tax advisors. 

  

	18.	CONDITION 

  

	18.1	Notwithstanding the date of execution of this Employment Agreement, this Employment Agreement and all transactions contemplated herein are conditional to the closing of
EndoCeutics’ contemplated initial public offering (“IPO”) and to the listing of its common shares on the NASDAQ Global Market, and shall become effective upon the earlier of (i) the accomplishment of these conditions or
(ii) the commencement date of the employment date of Dr. Labrie as mutually agreed by the parties (the “Effective Date”). 

  

	19.	LANGUAGE OF AGREEMENT 

  

	19.1	The parties have agreed that the present Employment Agreement and the Schedule A be drafted in the English language. Les parties aux présentes ont consenti à ce
que le présent contrat ainsi que les annexes soient rédigés en langue anglaise. 

 [THE SIGNATURES ARE
ON THE NEXT PAGE] 

 IN WITNESS WHEREOF, the parties hereto have executed this Employment Agreement. 
  

			
	ENDOCEUTICS, INC.
		
	By:	 	 /s/ Robert Després

		 	Robert Després, Chairman
		
	Date:	 	October 6, 2006
	
	DR. FERNAND LABRIE
	
	 /s/ Fernand Labrie

		
	Date:	 	October 6, 2006

 SCHEDULE A 
 CONFIDENTIALITY, PROPRIETARY INFORMATION AND 
 INVENTION AGREEMENT 
 This Schedule A forms an integral part of the employment agreement between EndoCeutics, inc. (“EndoCeutics”) and Dr. Fernand Labrie
(the “Employee”) (the “Employment Agreement”). 
 Since EndoCeutics will have to provide to the Employee
with some confidential information which EndoCeutics considers to be its property, EndoCeutics understands that the Employee will keep confidential all such information received from EndoCeutics and that the Employee will not communicate this
information in any way to any other party without having obtained EndoCeutic’s specific agreement in a written form beforehand. 
 The
present obligation of confidentiality and non-use of the information provided to the Employee will remain in effect for the duration of the Employment Agreement and for a period of ten (10) years following its termination. This obligation does
not apply to any information which: 
  

	a)	is or will subsequently become of public knowledge following publication or otherwise, and this, without fault on the Employee’s part; or 

  

	b)	was in the Employee’s possession before being transferred to the Employee by EndoCeutics and for which the Employee can provide proof of prior knowledge based on appropriate
documentation; or 

  

	c)	is later transmitted to the Employee by a third party who has the legal right to do so. 

 The Employee’s signature of the present is an indication that the Employee is not linked by any contract and that the Employee has no obligation to any other party which could prevent the Employee, in any way,
from respecting the Employee’s present obligation to EndoCeutics and this agreement, without any restriction or reservation. It is agreed that any written information as well as all materials that will be provided to the Employee in order to
execute the Employment Agreement will remain EndoCeutic’s property and will be returned to it immediately following their use. The Employee agrees not to identify or associate EndoCeutics nor to indicate the nature of the Employee’s
services or compounds that the Employee is making or working with for EndoCeutics to a third party without prior written acceptance on its part, except if such a disclosure is required by law. 
 All information which the Employee may divulge to EndoCeutics concerning the Employment Agreement must not be restricted by a secrecy agreement with a
third party nor must it be the property of someone else. Such information transmitted to EndoCeutics should 

 not be interpreted as leading to any obligation on EndoCeutics’s part. Moreover, as a consideration of the
Employment Agreement, EndoCeutics understands that the intellectual proprietary rights related to the inventions or discoveries achieved in the course of the Employee’s execution of engagement under the Employment Agreement (the
“Proprietary Rights”) are and will remain the property of EndoCeutics and its assigns and the Employee agrees to collaborate with EndoCeutics to the best of the Employee’s capacity to protect them in all territories. For that purpose,
the Employee hereby irrevocably assigns to EndoCeutics any and all right, title and interest that Employee may have or otherwise acquire in and to all the Proprietary Rights and also constitutes and appoints EndoCeutics as the Employee’s sole
and irrevocable agent and mandatory to sign and execute, on the Employee’s behalf, any assignment and/or patent application and/or other document required for the acknowledgment, or protection and/or enforcement of EndoCeutics’s rights.

 If it became necessary for the Employee to inform EndoCeutics of any confidential information (such a necessity being determined by
EndoCeutics on the basis of previous discussions with the Employee and following its acceptance of this information), EndoCeutics agrees to keep any such disclosures confidential, this confidential information being signed by the Employee before
being transmitted to EndoCeutics. 
 In the case that the Employee would transmit or use confidential information which EndoCeutics considers
to be its property and in violation of the above-mentioned terms and conditions, the Employee accepts, upon written request on EndoCeutics’s part, to pay, by way of liquidated damages and not in terms of penalty, the following: 
  

	a)	a sum of five thousand dollars ($5,000) for each divulgence; and 

  

	b)	an additional sum of ten thousand dollars ($10,000) for each day of this non-authorized use of EndoCeutics’s information; 

 and this, without any prejudice to EndoCeutics’s right to use an injunction to prevent any future use of this information. 
 The present convention must be interpreted in agreement with the laws of the Province of Quebec. EndoCeutics would appreciate receiving confirmation of
the Employee’s acceptance of the present contract by duly signing and returning to it the present letter. 

 La présente convention a été rédigée en anglais à la demande
expresse des parties. This agreement has been drafted in English at the specific request of the parties hereto. 
  

					
	ENDOCEUTICS, INC.	  		  	
			
	 /s/ Robert Després
	  		  	
	Robert Després, Chairman	  		  	
			
	COUNTERSIGNED THIS 6th DAY OF
OCTOBER, 2006 at Quebec (Quebec), to hold as acceptance	  		  	
			
	 /S/ Fernand Labrie
	  		  	
	Dr. FERNAND LABRIEEmployment Agreement between Registrant and Julie-Pascale Emond

 Exhibit 10.2 
 THIS EMPLOYMENT AGREEMENT, entered into at Quebec City, (Quebec), on the date hereinafter mentioned, 
  

	BETWEEN:	ENDOCEUTICS, INC., a corporation duly constituted, having its principal place of business at 2989, de la Promenade, Québec, Québec, G1W 2J5, herein acting and
represented by Dr Fernand Labrie, its President and Chief Executive Officer; 

 (hereafter “EndoCeutics”)

  

	AND;	JULIE-PASCALE ÉMOND, domiciled and residing at 174, Champagnat, Lévis, Québec, G6V 7L2; 

 (hereafter “Mrs. Émond”) 
 WITNESSED THE FOLLOWING: 
 WHEREAS EndoCeutics desires to secure an agreement from Mrs. Émond that Mrs. Émond will
provide her ongoing business time, energy and skills to EndoCeutics as an employee holding the position of Controller of EndoCeutics; 
 WHEREAS Mrs.
Émond desires to provide EndoCeutics with such agreement and obtain certain assurances from EndoCeutics; 
 NOW THEREFORE, in consideration of
the mutual promises and covenants set forth herein, the parties hereto agree as follows: 
  

	1.	EFFECTIVE DATE AND TERM OF EMPLOYMENT 

  

	1.1	The Employment Agreement shall begin on the Effective Date, as defined in Article 18 hereinafter, and shall continue until it is terminated pursuant to section 9 herein.

  

	2.	DUTIES 

  

	2.1	The main duties and responsibilities of Mrs. Émond pursuant to this Employment Agreement shall consist of those inherent to the functions of a controller. Mrs. Émond
shall also assume, in addition to the functions and duties inherent and related to her position, the functions and duties that the Chief Financial Officer of EndoCeutics may from time to time delegate to her. Mrs. Émond shall report directly
to the Chief Financial Officer of EndoCeutics. 

  

	3.	BASIC SALARY, BENEFITS AND EXPENSES 

  

	3.1	 EndoCeutics will pay to Mrs. Émond a base salary of CDN$130,000.00 per year, payable by 24 equal and consecutive installments of CDN$5,416.67 (or in such
equal and consecutive installments as are consistent with EndoCeutics’ current payroll practices), 

	 	 
less payroll deductions and all required withholdings, Mrs. Émond’s remuneration may be adjusted in accordance with EndoCeutics’ policies
and procedures. 

  

	3.2	Mrs. Émond will also be eligible to participate in such of EndoCeutics’ benefit plans as are now generally available or later available to executives of EndoCeutics,
subject to the terms of those plans. 

  

	3.3	Pursuant to EndoCeutics’ customary policies in force at the time of payment, Mrs. Émond shall be promptly reimbursed, against presentation of vouchers or receipts, for
all authorized expenses properly incurred by her on EndoCeutics’ behalf in the performance of her duties hereunder. 

  

	4.	BONUS 

  

	4.1	EndoCeutics further agrees to pay to Mrs. Émond, as an additional consideration, an annual bonus based on the performance of Mrs. Émond and on the achievement of the
objectives to be fixed by the Chief Executive Officer and the Board of directors of EndoCeutics from year to year. 

  

	4.2	Said bonus may reach up to 20% if targeted results and objectives are achieved as determined by the Compensation Committee. Said bonus shall be reviewed by the Compensation
Committee from year to year and shall be paid from the financial year-end of EndoCeutics. From the bonus amount, EndoCeutics will deduct all normal employment deductions including contributions to various governments. 

  

	5.	VACATION 

  

	5.1	Mrs. Émond is entitled to 5 weeks of paid vacation annually from the Effective Date onwards. Such vacations shall be consistent with EndoCeutics’ vacation policies.

  

	6.	STOCK OPTIONS 

  

	6.1	As Controller of EndoCeutics, and following the commencement of Mrs. Émond’s employment with EndoCeutics, Mrs. Émond will be eligible to a stock option under the
EndoCeutics’ Stock Option Plan to purchase EndoCeutics’ Common Shares (the “Option”). The Option will be governed by and granted pursuant to a separate stock option agreement and the Plan. In addition, Mrs. Émond
shall be entitled to participate in any stock option plan, stock appreciation rights, incentive stock plan or restricted stock plan or other similar plan that may be implemented from time to time by EndoCeutics and as recommended by the Compensation
Committee. 

  

	7.	LOYAL AND CONSCIENTIOUS PERFORMANCE 

  

	7.1	During the term of this Employment Agreement, Mrs. Émond shall devote all of her business time, energy and skills to the affairs of EndoCeutics and use her best efforts to
promote the interests of EndoCeutics; provided that, Mrs. Émond shall not be precluded from engaging in civic, charitable or religious activities which do not present any conflict 

	 	 
of interest with EndoCeutics or affect Mrs. Émond’s performance of duties and functions for EndoCeutics. 

  

	7.2	This Agreement shall not be interpreted to prohibit Mrs. Émond from making passive personal investments or conducting private business affairs if such activities do not
materially interfere with the services required under this Agreement. 

  

	8.	NON-COMPETITION AND NON-SOLICITATION 

  

	8.1	Mrs. Émond shall not, during the term of this Employment Agreement and for a period of twelve (12) months immediately following the termination of her employment, become
engaged, directly or indirectly as an employee, consultant, partner, principal, agent, proprietor, shareholder (other than a holding of shares listed on a stock exchange that does not exceed 2% of the outstanding shares so listed) or advisor, in a
business in the territory of the United States and Canada that (i) conducts research, development, marketing, sales or manufacturing activities in the field of breast and prostate cancer using antiandrogens, antiestrogens or SERMs and women’s
health and aging using DHEA, SERMs or SARMs and (ii) is a direct competitor of EndoCeutics. Mrs. Émond acknowledges that the restrictions contained in this Section 8.1 are properly required for the adequate protection of EndoCeutics’
businesses and that said restrictions do not materially affect her ability to obtain other employment. 

  

	8.2	Mrs. Émond shall not, during the term of this Employment Agreement and for a period of twelve (12) months immediately following the termination of her employment, directly or
indirectly solicit any employees of EndoCeutics and shall not solicit or induce or attempt to induce any person who were employees of or consultants to EndoCeutics at the time of such termination (or during the ninety (90) days immediately preceding
such termination), to terminate their employment or consulting agreement with EndoCeutics. 

  

	8.3	These Non-Competition (8.1) and Non-Solicitation (8.2) provisions shall not be applicable if EndoCeutics effects a Termination without Cause of Mrs. Émond’s
employment (as defined in section 9.3), or if Mrs. Émond’s employment is terminated following a merger or acquisition (as defined in section 9.4.). 

  

	8.4	Employee acknowledges and agrees that the agreements and covenants set forth in the Non-Competition (8.1) and Non-Solicitation (8.2) are reasonable and necessary for the protection
of the Company’s business interests, that irreparable injury will result to the Company if employee breaches any of the terms of said covenants, and that in the event of employees’s actual or threatened breach of any such covenants, the
Company will have no adequate remedy at law. Employee accordingly agrees that, in the event of any actual or threatened breach by employee of any of said covenants, the Company will be entitled to immediate injunctive and other equitable relief,
without bond and without the necessity of showing actual monetary damages. Nothing in this paragraph 8.4 will be construed as prohibiting the Company from pursuing any other remedies available to it for such breach or threatened breach, including
the recovery of any damages that it is able to prove. Each of the covenants in sections 8.1 and 8.2 will be construed as independent of any other covenants or other provisions of this Agreement. 

	9.	TERMINATION 

  

	9.1	Disability. If during the terms of this Agreement, Mrs. Émond becomes ill, disabled or otherwise incapacitated so as to be unable to perform her usual duties
(a) for a period in excess of one hundred and eighty (180) consecutive days and this incapacity has not been remedied within one (1) year of the first day of disability, or (b) for more than two hundred and seventy
(270) days in any consecutive eighteen (18) month period and this incapacity has not been remedied within eighteen (18) months of the first day of disability, then EndoCeutics shall have the right to terminate this Agreement, subject
only to applicable laws, on thirty (30) day’s notice to Mrs. Émond. Termination pursuant to this section 9.1 shall not affect any rights Mrs. Émond may otherwise have under any disability insurance policies in effect at the
time of such termination. 

  

	9.2	Discharge for cause. EndoCeutics may discharge Mrs. Émond and terminate her employment under this Agreement for cause without further liability to EndoCeutics. As
used in this section 9.2, “cause” shall mean any or all of the following: 

  

	 	(a)	gross or willful misconduct of Mrs. Émond during the course of her employment; 

  

	 	(b)	conviction of any criminal offence involving dishonesty, breach of trust or moral turpitude during the term of this Agreement; or 

  

	 	(c)	Mrs. Émond’s breach of any of the material terms of this Agreement. 

  

	9.3	Termination without cause. Upon thirty (30) days prior written notice, EndoCeutics may terminate this Agreement without cause. EndoCeutics shall incur no liability
in this regard except that it shall continue to pay Mrs. Émond the remuneration is entitled to at her then current rate for a nine (9) month period after termination if termination shall occur prior to the events mentioned in section
9.4. In addition, stock options that have vested shall be exercised by Mrs. Émond within a period of nine (9) months from the time of such termination or shall be automatically terminated immediately following such nine (9) month
period. All stock options that have not vested shall be immediately terminated. 

  

	9.4	Termination following merger or acquisition. If EndoCeutics merges or consolidates with another corporation, if substantially all of the assets of EndoCeutics are sold,
or if a majority of the outstanding stock of EndoCeutics is acquired by another person and Mrs. Émond’s employment is subsequently terminated by EndoCeutics or surviving entity other than for cause as described in 9.2, Mrs. Émond
shall be entitled to 12 months’ remuneration plus health benefits. 

 In addition to the foregoing, any outstanding stock
options (including substituted stock options of the acquiring or surviving corporation in such merger or acquisition) which have not vested in accordance with their terms will become fully vested and shall be exercised by Mrs. Émond within a
period of twelve (12) months from the time of such termination or shall be automatically terminated immediately following such twelve (12) month period. For purposes of this section 9.4, Mrs. Émond shall be entitled to treat a
material demotion in title or function or a physical relocation of worksite of more than 50 km as termination under this section 9.4, but only if Mrs. Émond expressly so notifies 

	 	 
EndoCeutics and terminates her employment hereunder within thirty (30) days of such demotion or relocation. If Mrs. Émond is offered a substantially
similar position with the surviving entity and a physical relocation (beyond a 50 km radius from Mrs. Émond’s regular worksite) is required by such position, Mrs. Émond’s refusal to accept such position shall not be treated
as subject to termination by Mrs. Émond under section 9.5 

  

	9.5	Voluntary termination by Mrs. Émond. In the event of voluntary termination by Mrs. Émond, Mrs. Émond shall be entitled only to those amounts that have
accrued to the date of termination in accordance with the terms hereof or are expressly payable under the terms of EndoCeutics applicable benefit plans or are required by applicable law. In addition, stock options that have vested shall be exercised
by Mrs. Émond within a period of nine (9) months from the time of such termination or shall be automatically terminated immediately following such nine (9) month period. All stock options that have not vested shall be immediately terminated.

  

	10.	CONFIDENTIALITY, PROPRIETARY INFORMATION AND INVENTION AGREEMENT 

  

	10.1	Mrs. Émond will execute and deliver to EndoCeutics a Confidentiality, Proprietary Information and Invention Agreement in the form attached hereto as Schedule A on or before
the Effective Date. 

  

	11.	WAIVER 

  

	11.1	The waiver of any term or condition of this Agreement by any party shall not be construed as a waiver of a subsequent breach or failure of the same term or condition, or a
waiver of any other term or condition of this Agreement. 

  

	12.	NOTICES 

  

	12.1	All notices, requests, demands, and other communications made in connection with this Employment Agreement shall be in writing and shall be deemed to have been duly given on
the date of delivery if delivered by hand delivery or five (5) days after mailing if mailed by certified or registered mail postage with prepaid return receipt requested. Addresses are as follows: 

  

			
	If to ENDOCEUTICS:	 	 2989, de la Promenade
 Québec,
Québec
 G1W 2J5
 Attn: Chairman

		
	If to Mrs. Émond:	 	 174, Champagnat
 Lévis, Québec

G6V 7L2

 Any party may change its address for notices by notices duly given pursuant to this section.

	13.	SEVERABILITY 

  

	13.1	In case any or some of the provisions of this Agreement shall be held to be invalid, illegal or unenforceable for any reason, such invalidity, illegality or unenforceability shall
not affect the other provisions of this Agreement, and this Agreement shall be constructed as if such invalid, illegal or unenforceable provision had never been contained herein. 

  

	14.	ENTIRE AGREEMENT AND MODIFICATIONS 

  

	14.1	Except as otherwise provided herein, this Employment Agreement, together with its Schedule A, represents the entire understanding between the parties with respect to the subject
matter hereof, and this Employment Agreement supersedes any and all prior understandings, agreements, plans and negotiations, written or oral, with respect to the subject matter hereof. All modifications to the Employment Agreement must be in
writing and signed by the parties against whom enforcement of such modification is sought, provided that no modification shall be enforceable against EndoCeutics unless signed by a duly authorized member of its Board or Directors.

  

	15.	GOVERNING LAW AND JURISDICTION 

  

	15.1	This Employment Agreement shall be governed by and construed in accordance with the laws of the Province of Quebec and the courts of the judicial district of Quebec shall have
jurisdiction. 

  

	16.	SUCCESSORS AND ASSIGNS 

  

	16.1	This Employment Agreement shall be binding upon and inure to the benefit of the executors, administrators, heirs, successors and assigns of the parties; provided, however, that this
Employment Agreement shall not be assignable by EndoCeutics or by Mrs. Émond. 

  

	17.	CONFIDENTIALITY 

  

	17.1	The parties hereby agree to keep the terms hereof confidential, subject to (i) any disclosure hereof required by law or regulation, and (ii) the ability of a party to review
the terms hereof with its legal, accounting and tax advisors. 

	18.	CONDITION 

  

	18.1	Notwithstanding the date of execution of this Employment Agreement, this Employment Agreement and all transactions contemplated herein are conditional to the closing of
EndoCeutics’ contemplated initial public offering (“IPO”) and to the listing of its common shares on the NASDAQ Global Market, and shall become effective upon the accomplishment of these conditions (the “Effective
Date”). 

  

	19.	LANGUAGE OF AGREEMENT 

  

	19.1	The parties have agreed that the present Employment Agreement and the Schedule A be drafted in the English language. Les parties aux présentes ont consenti à ce que le
présent contrat ainsi que les annexes soient rédigés en langue anglaise. 

 IN WITNESS WHEREOF, the parties hereto have
executed this Employment Agreement. 
  

			
	ENDOCEUTICS, INC.
		
	By:	 	/S/    FERNAND LABRIE
		 	Fernand Labrie, President and Chief Executive Officer
		
	Date:	 	December 14, 2006

  

			
	JULIE-PASCALE ÉMOND
		
		 	/S/    JULIE-PASCALE ÉMOND
		
	Date:	 	December 14, 2006

 SCHEDULE A 
 CONFIDENTIALITY, PROPRIETARY INFORMATION AND 
 INVENTION AGREEMENT 
 This Schedule A forms an integral part of the employment agreement between EndoCeutics, inc. (“EndoCeutics”) and JULIE-PASCALE
ÉMOND (the “Employee”) (the “Employment Agreement”). 
 Since EndoCeutics will have to provide to
the Employee with some confidential information which EndoCeutics considers to be its property, EndoCeutics understands that the Employee will keep confidential all such information received from EndoCeutics and that the Employee will communicate
this information in any way to any other party without having obtained the EndoCeutics’ specific agreement in a written form beforehand. 
 The present obligation of confidentiality and non-use of the information provided to the Employee will remain in effect for the duration of the Employment Agreement and for a period of ten (10) years following its termination. This
obligation does not apply to any information which: 
  

	a)	is or will subsequently become of public knowledge following publication or otherwise, and this, without fault on the Employees’ part; or 

  

	b)	was in the Employee’s possession before being transferred to the Employee by EndoCeutics and for which the Employee can provide proof of prior knowledge based on appropriate
documentation; or 

  

	c)	is later transmitted to the Employee by a third party who has the legal right to do so. 

 The Employee’s signature of the present is an indication that the Employee is not linked by any contract and the Employee has no obligation to any other party which could prevent the Employee, in any way, from
respecting the Employee’s present obligation to EndoCeutics and this, without any restriction or reservation. It is agreed that any written information as well as all materials that will be provided to the Employee in order to execute the
Employment Agreement will remain EndoCeutics’ property and will be returned to it immediately following their use. The Employee agrees not to identify or associate EndoCeutics nor to indicate the nature of the Employee’s services or
compounds that the Employee is making or working with for EndoCeutics to a third party without prior written acceptance on its part, except if such a disclosure is required by law. 
 All information which the Employee may divulge to EndoCeutics concerning the Employment Agreement must not be restricted by a secrecy agreement with a
third party nor must it be the property of someone else. Such information transmitted to EndoCeutics should not be interpreted as leading to any obligation on EndoCeutics’ part. Moreover, as a 

 
consideration of the Employment Agreement, EndoCeutics understands that the intellectual proprietary rights related to the inventions or discoveries achieved
in the course of the Employee engagement under the Employment Agreement (the “Proprietary Rights”) are and will remain EndoCeutics’ the property of EndoCeutics and its assigns and the Employee agrees to collaborate with EndoCeutics to
the best of the Employee’s capacity to protect them in all territories. For that purpose, the Employee hereby irrevocably assigns to EndoCeutics any and all right, title and interest that Employee may have or otherwise acquire in and to all the
Proprietary Rights and also constitutes and appoints EndoCeutics as the Employee’s sole and irrevocable agent and mandatory to sign and execute, on the Employee’s behalf, any assignment and/or patent application and/or other document
required for the acknowledgement, or protection and/or enforcement of EndoCeutics’ rights. In addition, the Employee hereby renounces to any moral rights she may have in the Proprietary Rights. 
 If it became necessary for the Employee to inform EndoCeutics of any confidential information (such a necessity being determined by EndoCeutics on the
basis of previous discussions with the Employee and following its acceptance of this information), EndoCeutics agrees to keep any such disclosures confidential, this confidential information being signed by the Employee before being transmitted to
EndoCeutics. 
 In the case that the Employee would transmit or use confidential information which EndoCeutics considers to be its property
and in violation of the above-mentioned terms and conditions, the Employee accepts, upon written request on EndoCeutics’ part, to pay, by way of liquidated damages and not in terms of penalty, the following: 
  

	a)	a sum of five thousand dollars ($5,000) for each divulgence; and 

  

	b)	an additional sum of ten thousand dollars ($10,000) for each day of this non-authorized use of EndoCeutics’ information; 

 and this, without any prejudice to EndoCeutics’ right to use an injunction to prevent any future use of this information. 
 The present convention must be interpreted in agreement with the laws of the Province of Quebec. EndoCeutics would appreciate receiving confirmation of
the Employee’s acceptance of the present contract by duly signing and returning to it the present letter. 
 La présente
convention a été rédigée en anglaisa à la demande expresse des parties. This agreement has been drafted in English at the specific request of the parties hereto. 
  

	
	ENDOCEUTICS, INC
	
	  
	 Fernand Labrie,
 President and Chief Executive
Officer

 COUNTERSIGNED THIS 14th DAY OF DECEMBER 2006 
 at Quebec (Quebec), to hold as acceptance 
 /s/    JULIE-PASCALE
ÉMOND 

 JULIE-PASCALE ÉMOND

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00117-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00117-of-00352.parquet"}]]